Focus on ß-blocker use and ß2-adrenergic receptor level
Appears in the following Collection
AbstractList of papers. The papers are removed from the thesis due to publisher restrictions.
Paper I: Grytli HH, Fagerland MW, Fosså SD, Taskén KA, Håheim LL. Use of ß-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate. 2013 Feb 15;73(3):250-60. doi:10.1002/pros.22564
Paper II: Grytli HH, Fagerland MW, Fosså SD, Taskén KA. Association between use of ß-blockers and prostate cancer- specific survival; a cohort study of 3561 prostate cancer patients with high risk or metastatic disease. Eur Urol. 2013 Jan 14. pii: S0302-2838(13)00010-9. [Epub ahead of print] doi:10.1016/j.eururo.2013.01.007
Paper III: Grytli HH, Ramberg H, Wang W, Braadland PR, Øgren O, Eide T, Krobert KA, Berge V, Paus E, Bjartell A, Levy FO, Svindland A, Taskén KA. The level of ß2-adrenergic receptor in prostate cancer tissue is associated with development of castration resistant prostate cancer: a pilot study. Submitted.